Literature DB >> 3221361

Myasthenia gravis in the cat.

R J Joseph1, J M Carrillo, V A Lennon.   

Abstract

Myasthenia gravis (MG) was diagnosed in four cats--one had an apparently congenital form and three had the acquired autoimmune form. All four cats were examined because of episodes of weakness including gait abnormalities, voice change, neck ventroflexion, and regurgitation. Palpebral reflexes were absent in all cats. Administration of edrophonium chloride resulted in transient resolution of clinical signs in all four cats. Three cats were tested for the presence of serum autoantibodies against acetylcholine receptor (AChR) by radioimmunoassay. Two cats with acquired MG had anti-AChR antibody titers of 10.5 and 96.8 nmol/l (normal, less than or equal to 0.03 nmol/l). Antibodies were not detected in the cat with presumptive congenital MG. All four cats were treated with pyridostigmine bromide. Two cats with acquired MG were euthanatized because of clinical deterioration. The third cat with acquired MG has been asymptomatic since 2 months after diagnosis. The cat with presumed congenital MG is alive 3 years after diagnosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3221361     DOI: 10.1111/j.1939-1676.1988.tb02797.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  3 in total

Review 1.  Classification of myasthenia gravis and congenital myasthenic syndromes in dogs and cats.

Authors:  Thomas Mignan; Mike Targett; Mark Lowrie
Journal:  J Vet Intern Med       Date:  2020-07-15       Impact factor: 3.333

2.  Risk Factors and Outcomes in Cats with Acquired Myasthenia Gravis (2001-2012).

Authors:  D W Hague; H D Humphries; M A Mitchell; G D Shelton
Journal:  J Vet Intern Med       Date:  2015-08-26       Impact factor: 3.333

3.  Long-term outcome of cats with acquired myasthenia gravis without evidence of a cranial mediastinal mass.

Authors:  Thomas Mignan; Laurent Garosi; Mike Targett; Mark Lowrie
Journal:  J Vet Intern Med       Date:  2019-11-20       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.